Adelia Therapeutics

Adelia Therapeutics is a U.S.-based biopharmaceutical company focused on proprietary psychedelic and tryptamine-derived therapeutics for central nervous system and mental health disorders. The company developed a discovery platform centered on selectively deuterated psychedelic molecules, related delivery methods, and therapeutic regimens intended to improve dosing efficacy, pharmacokinetics, and therapeutic index. In December 2020, Adelia was acquired by Cybin in an all-stock transaction, and its assets, intellectual property, and scientific team were integrated into Cybin’s psychedelic drug development portfolio. Adelia’s platform and patent estate helped support the advancement of Cybin programs including CYB003 and CYB004, which target mood, anxiety, and addiction-related indications.